Figure legends
Figure 1. ODs for the treatment of Haemophilia A and B (n. 41).
Figure 2. Haemophilia ‘active’ ODs classification according to
MOA (n. 26).
Figure 3. Mechanisms of action of novel non-factor therapeutics
for haemophilia. Haemostatic nonfactor agents in varying phases of
development include substitution therapies (Emicizumab) for FVIII that
an restore factor Xa generation and rebalancing therapies, which knock
down or disrupt the natural anticoagulants (small interfering RNA to AT
and PS, monoclonal antibodies to TFPI), to augment haemostasis.